Dr. Reddy’s makes Day-1 GLP-1 entry with Obeda 

Key Highlights: 

• Dr. Reddy’s has launched Obeda in India, marking its Day-1 entry into the GLP-1 space post patent expiry and becoming the first Indian company to secure DCGI approval for generic semaglutide. The once-weekly injectable is indicated for type 2 diabetes, reinforcing the company’s push into advanced metabolic therapies 

• Backed by a head-to-head Phase III study (n=312), Obeda demonstrated non-inferior efficacy and comparable safety to the innovator, with similar glycaemic control across HbA1c, fasting, and post-prandial glucose levels, and no anti-drug antibodies detected. The therapy is available in 2mg and 4mg pre-filled disposable pens (≥4 weekly doses/pen), priced at ~₹4,200/month, supported by fully in-house API and formulation development 

• Beyond the launch, Dr. Reddy’s is building a broader GLP-1 ecosystem, planning global rollouts, advancing a full-spectrum metabolic portfolio, and introducing its ‘SemaKare’ patient support program with digital and counselling support. The company also aims to establish metabolic centres of excellence across India, integrating treatment, education, and nutrition support to improve long-term outcomes  

Implications: 

Obeda’s Day‑1 launch with DCGI approval and head‑to‑head Phase III data positions Dr. Reddy’s as a clinically credible, early GLP‑1 player, even at a higher ~₹4,200/month price point than newer low‑cost entrants. 
By backing the product with in‑house peptide manufacturing, the SemaKare support program, and plans for metabolic centres of excellence, Dr. Reddy’s is clearly playing a long‑game in metabolic disease, using Obeda as the anchor for a broader, globally scalable GLP‑1 and cardiometabolic franchise  

Source: Dr. Reddy’s | Image: Dr. Reddy’s